In this phase 3, multinational, randomised trial, , progression-free survival outcomes with nivolumab plus ipilimumab were superior to those with chemotherapy in the first-line treatment of MSI-H or dMMR metastatic colorectal cancer.
Grade 3 and 4 treatment-related toxic effects were consistent with the established profiles of each individual drug, and no new safety concerns were identified.
Lynch Syndrome Ireland 